BioStock published an article on 8 December 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an emergency treatment targeting sepsis, has been able to make several key...
Read MoreBioStock published an article on 26 November 2020 about Aptahem, which can be read in full below. Biotechnology company Aptahem, that develops its drug candidate Apta-1 for the treatment of life-threatening organ and tissue damage caused by sepsis, was...
Read MoreAptahem AB (publ), announce today that the company enters a collaboration agreement with the German company Granzer Regulatory Consulting and Services to prepare for applications to the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). Granzer...
Read MoreBioStock published an article on 15 October 2020 about Aptahem, which can be read in full below. On September 25, Bert Junno was elected Chairman of the Board of the biotech company Aptahem. As a founder of several companies...
Read MoreAptahem AB (publ), announce today that the company’s largest shareholder, Ivar Nordqvist, suggests Dr Bert Junno to be elected new Chairman of the Board at the coming Extraordinary General Meeting on 25 September 2020. This after the former Chairman...
Read MoreAptahem AB (publ), announce today that the Chairman of the Board of Directors, Kjell G Stenberg, has requested his own resignation from the Board. Due to this, the Board of Directors will call for an Extraordinary General Meeting to...
Read MoreAptahem AB, a leading developer of aptamer-based drugs, announced today that the company is now starting large-scale manufacturing after LGC Bioresearch Technologies Inc. (LGC) completed the Process Development (PD) work enabling larger Pilot scale production campaigns of Apta -1....
Read MoreBioStock published an article on 10 July 2020 about Aptahem, which can be read in full below. Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the University Health Network in Toronto. The collaboration will...
Read MoreAptahem (publ) today announced the beginning of a collaboration with the University Health Network, a research hospital affiliated with University of Toronto in Canada. The collaboration aims to evaluate the anti-coagulant Apta-1 as an inhibitor of hyper inflammatory response...
Read MoreBioStock published an article on 1 July 2020 about Aptahem, which can be read in full below. At the end of last year, Aptahem entered a consortium with Örebro University with the aim of evaluating new strategies to reduce...
Read More